13 Best Psychedelic Stocks to Invest in Now

Page 10 of 11

2. Sage Therapeutics, Inc. (NASDAQ:SAGE)

Number of Hedge Fund Holders: 32 

Sage Therapeutics, Inc. (NASDAQ:SAGE) known for its FDA-approved postpartum depression drug Zurzuvae, is acquired by Supernus Pharmaceuticals in a deal valued at up to $795 million. The agreement, announced in June 2025, includes $561 million in cash and contingent value rights, aiming to expand Supernus’s neuropsychiatric portfolio while integrating Sage’s CNS discovery platform. The merger is expected to deliver up to $200 million in annual cost synergies and strengthen Supernus’s 2026 financial outlook.

Sage Therapeutics, Inc. (NASDAQ:SAGE) recently saw workforce reductions, with around 338 employees laid off in 2025. Despite the downsizing, the company continues to advance its clinical pipeline, focusing on SAGE-319 for neurodevelopmental disorders, with Phase 1 data expected by late 2025, and SAGE-324, targeting seizures in developmental and epileptic encephalopathies, with updates anticipated mid-year.

Earlier in 2025, Sage Therapeutics, Inc. (NASDAQ:SAGE) rejected a takeover offer from Biogen, citing undervaluation, signaling its strategic focus on maximizing shareholder value. The company remains committed to positioning Zurzuvae as a first-line therapy for postpartum depression, supported by expanded commercialization efforts including a strengthened sales force and digital marketing campaigns.

Page 10 of 11